Search | Clinical Trials Finder

Conditions: COVID-19, Viral Respiratory Illnesses
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 55 Years to 120 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Kissimmee, Florida • Acworth, Georgia • Lake Charles, Louisiana + 1 more

Conditions: Crohn's Disease
Interventions: Placebo, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 73
States / cities: Anaheim, California • Oceanside, California • Poway, California + 42 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: losmapimod, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more

Conditions: Single Ventricle Heart Disease
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Mezzion Pharma Co. Ltd; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 22 more

Conditions: Breast Cancer
Interventions: Ruxolitinib, Capecitabine, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 80
States / cities: Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more

Conditions: Tobacco Use Cessation
Interventions: Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test; Drug · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Metronidazole (male partner), Placeob (male partner); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 50 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pell City, Alabama

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib Disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nyack, New York

Conditions: Psoriasis, Skin Diseases
Interventions: Orismilast modified release tablets, Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Overactive Bladder
Interventions: dexmecamylamine, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 125
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more

Conditions: Alopecia
Interventions: Setipiprant, Placebo, Finasteride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more

Conditions: Osteoarthritis, Knee, Pain
Interventions: V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more

Conditions: Non Small Cell Lung Cancer
Interventions: ARQ 197, Erlotinib, Placebo; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Burbank, California • Santa Monica, California • Torrington, Connecticut + 14 more

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Colorectal Adenoma, Colorectal Carcinoma
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy
Interventions: JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more

Conditions: Myocardial Ischemia
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Behçet's Syndrome
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more

Conditions: Obsessive-compulsive Disorder
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Transcept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more

Conditions: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: TRx0237, Placebo; Drug
Lead sponsor: TauRx Therapeutics Ltd; Industry
Eligibility: Up to 79 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more

Conditions: Healthy Volunteers
Interventions: DZD2269, placebo; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Secaucus, New Jersey

Search by objective public record fields.

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Fontan Udenafil Exercise Longitudinal Assessment Trial

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Microvascular Coronary Disease In Women: Impact Of Ranolazine

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

A Study of DZD2269 in Healthy Adult Participants